Eyevansys initiates trial for PST-611 in dry AMD assessing safety and tolerability
Eyevansys is conducting a clinical trial to evaluate the safety and tolerability of PST-611 in patients with dry AMD.
Asset / Drug
Drug and asset intelligence for Eyevansys with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.